Active site mutations and substrate inhibition in human sulfotransferase 1A1 and 1A3

被引:48
作者
Barnett, AC
Tsvetanov, S
Gamage, N
Martin, JL
Duggleby, RG
McManus, ME
机构
[1] Univ Queensland, Fac Biol & Chem Sci, Sch Biomed Sci, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia
[3] Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia
关键词
D O I
10.1074/jbc.M312253200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human SULT1A1 is primarily responsible for sulfonation of xenobiotics, including the activation of promutagens, and it has been implicated in several forms of cancer. Human SULT1A3 has been shown to be the major sulfotransferase that sulfonates dopamine. These two enzymes shares 93% amino acid sequence identity and have distinct but overlapping substrate preferences. The resolution of the crystal structures of these two enzymes has enabled us to elucidate the mechanisms controlling their substrate preferences and inhibition. The presence of two p-nitrophenol (pNP) molecules in the crystal structure of SULT1A1 was postulated to explain cooperativity at low and inhibition at high substrate concentrations, respectively. In SULT1A1, substrate inhibition occurs with pNP as the substrate but not with dopamine. For SULT1A3, substrate inhibition is found for dopamine but not with pNP. We investigated how substrate inhibition occurs in these two enzymes using molecular modeling, site-directed mutagenesis, and kinetic analysis. The results show that residue Phe-247 of SULT1A1, which interacts with both p-nitrophenol molecules in the active site, is important for substrate inhibition. Mutation of phenylalanine to leucine at this position in SULT1A1 results in substrate inhibition by dopamine. We also propose, based on modeling and kinetic studies, that substrate inhibition by dopamine in SULT1A3 is caused by binding of two dopamine molecules in the active site.
引用
收藏
页码:18799 / 18805
页数:7
相关论文
共 45 条
[1]   Current status of the cytosolic sulfotransferases in the activation of promutagens and procarcinogens metabolic [J].
Banoglu, E .
CURRENT DRUG METABOLISM, 2000, 1 (01) :1-30
[2]   Crystal structure of human catecholamine sulfotransferase [J].
Bidwell, LM ;
McManus, ME ;
Gaedigk, A ;
Kakuta, Y ;
Negishi, M ;
Pedersen, L ;
Martin, JL .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (03) :521-530
[3]   A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily [J].
Blanchard, RL ;
Freimuth, RR ;
Buck, J ;
Weinshilboum, RM ;
Coughtrie, MWH .
PHARMACOGENETICS, 2004, 14 (03) :199-211
[4]   Analysis of the substrate specificity of human sulfotransferases SULT1A1 and SULT1A3: Site-directed mutagenesis and kinetic studies [J].
Brix, LA ;
Barnett, AC ;
Duggleby, RG ;
Leggett, B ;
McManus, ME .
BIOCHEMISTRY, 1999, 38 (32) :10474-10479
[5]   Structural characterization of human aryl sulphotransferases [J].
Brix, LA ;
Duggleby, RG ;
Gaedigk, A ;
McManus, ME .
BIOCHEMICAL JOURNAL, 1999, 337 :337-343
[6]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[7]   Arginine residues in the active site of human phenol sulfotransferase (SULT1A1) [J].
Chen, GP ;
Chen, XR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (38) :36358-36364
[8]   Carboxyl residues in the active site of human phenol sulfotransferase (SULT1A1) [J].
Chen, GP ;
Rabjohn, PA ;
York, JL ;
Wooldridge, C ;
Zhang, DQ ;
Falany, CN ;
Radominska-Pandya, A .
BIOCHEMISTRY, 2000, 39 (51) :16000-16007
[9]  
CHOU HC, 1995, CANCER RES, V55, P525
[10]   A single amino acid, Glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3 [J].
Dajani, R ;
Hood, AM ;
Coughtrie, MWH .
MOLECULAR PHARMACOLOGY, 1998, 54 (06) :942-948